The distribution agreement covers the sale of AxiaLIF products in China with the exception of Hong Kong, Macau and Taiwan. TranS1’s AxiaLIF implants were granted a registration certificate by China’s State Food and Drug Administration, and the remaining instrumentation is expected to receive their respective registration in the fourth quarter of 2012.
More Articles on Orthopedic Devices:
Smith & Nephew Launches TRIGEN Low-Profile Screw
Mazor Robotics Finalizes $15M in Financing
Implantate Extends Contracts of All Board Members
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.